ACME LaboratoriesDHA:ACMELAB +0.37%82 EBITDA Margin % is 14.93% as of Mar. 2026, which is 28% below its 10-year median of 20.70. GuruFocus rates DHA:ACMELAB with a GF Score™ of 82/100 and a GF Value™ of BDT124.74 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, ACME Laboratories ranks better than 64.71% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ACME Laboratories's EBITDA for the
three
months ended in Mar. 2026 was BDT1,559 Mil. ACME Laboratories's Revenue for the
three
months ended in Mar. 2026 was BDT10,440 Mil. Therefore, ACME Laboratories's EBITDA margin for the quarter that ended in Mar. 2026 was 14.93%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ACME Laboratories EBITDA Margin % Related Terms
ACME Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories (DHA:ACMELAB) has a EBITDA Margin % of 14.93% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ACME Laboratories and its competitors. This is 28% below median its historical median of 20.70. Over the past decade, ACME Laboratories' EBITDA Margin % has ranged from 17.03 to 23.22. According to the industry distribution chart, ACME Laboratories ranks #337 out of 955 companies in the Drug Manufacturers industry, placing it in the top 35.3%.
Is ACME Laboratories' EBITDA Margin % too high?
ACME Laboratories' current EBITDA Margin % of 14.93% is 28% below median its 10-year median of 20.70. Over the past 10 years, this metric has ranged from a low of 17.03 to a high of 23.22. The Drug Manufacturers industry median EBITDA Margin % is 12.44. ACME Laboratories' value of 14.93% is 20% above this industry median. Based on the distribution chart, ACME Laboratories ranks #337 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #337 out of 955 companies for EBITDA Margin %. This puts ACME Laboratories in the upper half of its industry. The industry median EBITDA Margin % is 12.44. ACME Laboratories' value of 14.93% is 20% above this benchmark. Historically, ACME Laboratories' own EBITDA Margin % has ranged from 17.03 to 23.22 over the past decade. While the company's 10-year median is 20.70 vs. the industry median of 12.44, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current EBITDA Margin % of 14.93% is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current EBITDA Margin % is 14.93%, which is 28% below median its own 10-year median of 20.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT124.74, compared to a current price of BDT81.30 — trading 34.8% below its estimated fair value. The current EBITDA Margin % is 14.93%, which is 28% below median its 10-year median of 20.70 and 20% above the Drug Manufacturers industry median of 12.44. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current EBITDA Margin % is 14.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT81.30 is trading 34.8% below its estimated GF Value™ of BDT124.74.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
EBITDA Margin %: 14.93% (28% below median its 10-year median of 20.70)
GF Value™: BDT124.74 vs. price of BDT81.30 (34.8% below fair value)
Industry Position: 20% above the Drug Manufacturers median (#337 of 955)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
